Ajanta Pharma Reports Robust Q2 FY27 With PAT Up 49% YoY
Ajanta Pharma Ltd 路 Financial Result 路 30 Oct 2026, 6:29 pm
Ajanta Pharma Reports Robust Q2 FY27 With PAT Up 49% YoY Ajanta Pharma reported strong Q2 FY27 consolidated revenue from operations of Rs. 1,794 cr., up 33% YoY. Adjusted EBITDA grew 47% YoY to Rs. 543 cr. with margins at 30%, while net profit rose 49% YoY to Rs. 388 cr. (PAT margin at 22%). Branded generics revenue grew 23% YoY to Rs. 1,182 cr., supported by India (+16%), Asia (+18%), and Africa (+41%). US Generics posted 41% YoY growth to Rs. 484 cr. For H1 FY27, revenue reached Rs. 3,420 cr. (+29% YoY) with PAT of Rs. 722 cr. (+40% YoY).
Original exchange filing (PDF)
More announcements from Ajanta Pharma Ltd
- The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 16, 2026 for Aayush Agrawal, .... 路 17 Nov 2026
- The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 09, 2026 for Aayush Agrawal, .... 路 09 Nov 2026
- Pls find enclosed Earnings Call Written Transcript 路 04 Nov 2026
- Pls find enclosed Audio recording of Earnings Call 路 30 Oct 2026
- Ajanta Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 30 Oct 2026
- Pls find enclosed Financial Results for the quarter ended 30.09.2026. 路 30 Oct 2026
- The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 19, 2026 for Aayush Agrawal, trustee .... 路 21 Oct 2026
- Pls find enclosed Earnings Conference Call Intimation. 路 30 Oct 2026
